Faeth Therapeutics Finalizes $150M ATM Offering Agreement; Preferred Stock Converts, Massively Increasing Outstanding Shares

summarizeSummary

Faeth Therapeutics entered into an agreement for a $150 million At-The-Market offering, while also reporting a preferred stock conversion that massively increased its outstanding common shares.

check_boxKey Events

• ATM Offering Agreement Finalized

  Faeth Therapeutics entered into a Sales Agreement with TD Securities (USA) LLC for an At-The-Market (ATM) offering, allowing it to sell up to $150 million of common stock. This formalizes the program initiated by the S-3ASR filed on the same day.

• Massive Potential Dilution from ATM

  The $150 million ATM program represents approximately 8 times the company's current market capitalization, indicating extreme potential dilution for existing shareholders if fully utilized.

• Significant Preferred Stock Conversion

  24,435,594 shares of Series B Preferred Stock automatically converted into an equal number of common shares on June 15, 2026.

• Outstanding Shares Increase 18-Fold

  The preferred stock conversion increased the total outstanding common stock from approximately 1.3 million to 25.7 million shares, resulting in an approximately 18-fold increase in share count.

auto_awesomeAnalysis

Faeth Therapeutics has formalized an At-The-Market (ATM) offering program to sell up to $150 million in common stock, an amount significantly exceeding its current market capitalization. This capital raise is critical given the company's prior "going concern" warning. Concurrently, a large conversion of preferred stock into common stock has already increased the outstanding share count by approximately 18-fold, resulting in substantial dilution for existing shareholders.